Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ticagrelor - AstraZeneca

Next Previous
Drug Profile

Ticagrelor - AstraZeneca

Alternative Names: AR-C-126532; AZD-6140; Brilinta; Brilique

Latest Information Update: 23 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; The Medicines Company; Uppsala University; Vanderbilt University
  • Class Amines; Anti-infectives; Antianaemics; Antibacterials; Antithrombotics; Azoles; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Purine nucleosides; Pyrimidines; Ribonucleosides; Small molecules; Vascular disorder therapies
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Registered Cardiovascular disorders; Stroke
  • Phase II Abdominal aortic aneurysm; Community-acquired pneumonia; Coronary artery disease
  • Discontinued Peripheral arterial disorders; Vaso-occlusive crisis

Most Recent Events

  • 05 Aug 2024 AstraZeneca initiates a phase I trial (In volunteers) in Germany (PO) (NCT06554821)
  • 09 Jan 2024 No development reported - Preregistration for Cardiovascular disorders (Prevention) in China (PO) (AstraZeneca pipeline; January 2024)
  • 09 Jan 2024 No development reported - Preregistration for Cardiovascular disorders (Prevention) in Japan (PO) (AstraZeneca pipeline; January 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top